| Active substance | Durvalumab |
| Holder | AstraZeneca |
| Status | Running |
| Indication | Imfinzi® (durvalumab) in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment followed by adjuvant Imfinzi® monotherapy for the treatment of adults with resectable gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC). |
| Public documents | |
| Last update | 27/05/2026 |